Works matching DE "EMPAGLIFLOZIN"
Results: 1022
Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes.
- Published in:
- Heart & Vessels, 2020, v. 35, n. 10, p. 1378, doi. 10.1007/s00380-020-01621-0
- By:
- Publication type:
- Article
Differences in effects of some newer-generation anti-diabetics on diabetic retinopathy versus nephropathy.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2024, v. 262, n. 4, p. 1371, doi. 10.1007/s00417-023-06353-1
- By:
- Publication type:
- Article
Empagliflozin: a potential anticancer drug.
- Published in:
- Discover Oncology, 2023, v. 14, n. 1, p. 1, doi. 10.1007/s12672-023-00719-x
- By:
- Publication type:
- Article
A UPLC/DAD method for simultaneous determination of empagliflozin and three related substances in spiked human plasma.
- Published in:
- BMC Chemistry, 2019, v. 13, n. 1, p. N.PAG, doi. 10.1186/s13065-019-0604-9
- By:
- Publication type:
- Article
Evaluation of empagliflozin efficacy as a promising anti-aging treatment in mice: In-vivo study.
- Published in:
- Pharmacia (0428-0296), 2024, v. 71, n. 1, p. 1, doi. 10.3897/pharmacia.71.e116184
- By:
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences in adults.
- Published in:
- Diabetes & Primary Care, 2023, v. 25, n. 1, p. 9
- Publication type:
- Article
SGLT2 inhibitors: Indications, doses and licences (England, Scotland and Wales).
- Published in:
- Diabetes & Primary Care, 2021, v. 23, n. 6, p. 175
- Publication type:
- Article
Comparison of Renal and Metabolic Effects of Empagliflozin and Dapagliflozin on Type 2 Diabetes-Induced Rats.
- Published in:
- 2022
- By:
- Publication type:
- Abstract
Effect of sodium-glucose transporter 2 inhibitors on bone.
- Published in:
- Journal of Parathyroid Disease, 2023, v. 11, n. 1, p. 1, doi. 10.34172/jpd.2023.11225
- By:
- Publication type:
- Article
Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes.
- Published in:
- Healthcare (2227-9032), 2022, v. 10, n. 7, p. 1153, doi. 10.3390/healthcare10071153
- By:
- Publication type:
- Article
Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-57871-9
- By:
- Publication type:
- Article
Empagliflozin suppresses hedgehog pathway, alleviates ER stress, and ameliorates hepatic fibrosis in rats.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-46288-5
- By:
- Publication type:
- Article
Empagliflozin induces the transcriptional program for nutrient homeostasis in skeletal muscle in normal mice.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-45390-y
- By:
- Publication type:
- Article
Clinical effects of SGLT2 inhibitors in seven persons with HNF1A‐MODY (MODY3).
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 10, p. 1, doi. 10.1111/dme.15387
- By:
- Publication type:
- Article
Efficacy and safety of sodium–glucose co‐transporter‐2 inhibitors in kidney transplant recipients with diabetes mellitus.
- Published in:
- Diabetic Medicine, 2024, v. 41, n. 8, p. 1, doi. 10.1111/dme.15383
- By:
- Publication type:
- Article
Epigastric pain and partial ptosis.
- Published in:
- 2023
- By:
- Publication type:
- Test/Instrument
Clinical care and other categories posters: Ethnicity.
- Published in:
- Diabetic Medicine, 2021, v. 38, p. 1, doi. 10.1111/dme.35_14556
- Publication type:
- Article
Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE.
- Published in:
- Diabetic Medicine, 2020, v. 37, n. 4, p. 593, doi. 10.1111/dme.14262
- By:
- Publication type:
- Article
Use of glucose‐lowering drugs in Hungary between 2008 and 2017: the increasing use of novel glucose‐lowering drug groups.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 12, p. 1612, doi. 10.1111/dme.14117
- By:
- Publication type:
- Article
Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 11, p. 1494, doi. 10.1111/dme.14076
- By:
- Publication type:
- Article
Diabetes management gains: teaching old dogs new tricks.
- Published in:
- Diabetic Medicine, 2019, v. 36, n. 9, p. 1072, doi. 10.1111/dme.14068
- By:
- Publication type:
- Article
SGLT2 inhibitors in Type 1 diabetes: is this the future?
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 12, p. 1642, doi. 10.1111/dme.13791
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic profile of thesodium-glucose co-transporter-2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial.
- Published in:
- Diabetic Medicine, 2018, v. 35, n. 8, p. 1096, doi. 10.1111/dme.13629
- By:
- Publication type:
- Article
Fournier's gangrene in a man on empagliflozin for treatment of Type 2 diabetes.
- Published in:
- Diabetic Medicine, 2017, v. 34, n. 11, p. 1646, doi. 10.1111/dme.13508
- By:
- Publication type:
- Article
Empagliflozin has favourable effect on frontal plane QRS‐T angle in diabetic patients with cardiovascular disease.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2022, v. 47, n. 11, p. 1783, doi. 10.1111/jcpt.13734
- By:
- Publication type:
- Article
Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta‐analysis based on randomized controlled trials.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2022, v. 47, n. 3, p. 270, doi. 10.1111/jcpt.13521
- By:
- Publication type:
- Article
Protective effect of empagliflozin against palmitate-induced lipotoxicity through AMPK in H9c2 cells.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1228646
- By:
- Publication type:
- Article
Empagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1295463
- By:
- Publication type:
- Article
Dapagliflozin versus empagliflozin in patients with chronic kidney disease.
- Published in:
- Frontiers in Pharmacology, 2023, v. 14, p. 01, doi. 10.3389/fphar.2023.1227199
- By:
- Publication type:
- Article
Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1186579
- By:
- Publication type:
- Article
Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1195124
- By:
- Publication type:
- Article
Economic Spectrofluorometric Bioanalysis of Empagliflozin in Rats' Plasma.
- Published in:
- Journal of Analytical Methods in Chemistry, 2021, p. 1, doi. 10.1155/2021/9983477
- By:
- Publication type:
- Article
Empagliflozin: A Review in Symptomatic Chronic Heart Failure.
- Published in:
- Drugs, 2022, v. 82, n. 16, p. 1591, doi. 10.1007/s40265-022-01778-0
- By:
- Publication type:
- Article
Empagliflozin: A Review in Type 2 Diabetes.
- Published in:
- Drugs, 2018, v. 78, n. 10, p. 1037, doi. 10.1007/s40265-018-0937-z
- By:
- Publication type:
- Article
Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys.
- Published in:
- Frontiers in Physiology, 2019, p. N.PAG, doi. 10.3389/fphys.2019.00271
- By:
- Publication type:
- Article
Effects of empagliflozin on the expression of kisspeptin gene and reproductive system function in streptozotocin-induced diabetic male rats.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.1059942
- By:
- Publication type:
- Article
Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.917761
- By:
- Publication type:
- Article
Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.907984
- By:
- Publication type:
- Article
Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.802992
- By:
- Publication type:
- Article
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
- Published in:
- Frontiers in Endocrinology, 2022, v. 13, p. 1, doi. 10.3389/fendo.2022.836455
- By:
- Publication type:
- Article
Use of Oral Empagliflozin to Obtain Optimal Blood Sugar Levels for Conducting <sup>18</sup> F-FDG PET-CT in Patients with Hyperglycemia—A Pilot Study.
- Published in:
- World Journal of Nuclear Medicine, 2023, v. 22, n. 3, p. 191, doi. 10.1055/s-0043-1771283
- By:
- Publication type:
- Article
Evaluating the effectiveness and safety of empagliflozin versus liraglutide in managing diabetic dyslipidemia: An observational study.
- Published in:
- Asian Journal of Medical Sciences, 2024, v. 15, n. 7, p. 137, doi. 10.3126/ajms.v15i7.65428
- By:
- Publication type:
- Article
Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 5, p. 893, doi. 10.1007/s13300-024-01555-0
- By:
- Publication type:
- Article
A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01).
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 2, p. 533, doi. 10.1007/s13300-023-01526-x
- By:
- Publication type:
- Article
Long-Term Effectiveness of Quadruple Combination Therapy with Empagliflozin Versus Basal Long-Acting Insulin Therapy in Patients with Type 2 Diabetes: 3-Year Retrospective Observational Study.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 9, p. 1471, doi. 10.1007/s13300-023-01437-x
- By:
- Publication type:
- Article
Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 11/12, p. 1891, doi. 10.1007/s13300-022-01323-y
- By:
- Publication type:
- Article
Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 9, p. 1621, doi. 10.1007/s13300-022-01296-y
- By:
- Publication type:
- Article
The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 3, p. 489, doi. 10.1007/s13300-022-01221-3
- By:
- Publication type:
- Article
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 2, p. 241, doi. 10.1007/s13300-022-01204-4
- By:
- Publication type:
- Article
Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.
- Published in:
- Diabetes Therapy, 2022, v. 13, n. 1, p. 25, doi. 10.1007/s13300-021-01173-0
- By:
- Publication type:
- Article